<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04662151</url>
  </required_header>
  <id_info>
    <org_study_id>AT-100/001</org_study_id>
    <nct_id>NCT04662151</nct_id>
  </id_info>
  <brief_title>Phase 1b Study on AT-100 Intervention (rhSP-D) in Preterm Neonates at High Risk for Development of Bronchopulmonary Dysplasia (BPD)</brief_title>
  <official_title>A Phase 1b, Randomized, Open-Label, Dose-Determined Study Evaluating the Safety and Tolerability Profile of Intervention With AT-100 (rhSP-D) in Preterm Neonates at High Risk for the Development of Bronchopulmonary Dysplasia (BPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Airway Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Airway Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if an investigational drug, AT-100, can reduce the&#xD;
      occurrence of Bronchopulmonary Dysplasia (BPD) in babies born premature, as compared to&#xD;
      babies born premature who receive an air-sham alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 1b portion is a randomized, dual-armed, dose escalation study to establish the safest &amp; most tolerated AT-100 dose tested as compared to air-sham alone.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of AT-100</measure>
    <time_frame>From time of initial AT-100 dosing until end of the study participation up to 36 Weeks Postmenstrual Age (PMA)</time_frame>
    <description>Dose escalation of AT-100 up to the highest tolerated and safety tested dose level in order to assess safety and tolerability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BPD or death</measure>
    <time_frame>At 36 Weeks PMA</time_frame>
    <description>Incidence of BPD or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time on mechanical ventilation</measure>
    <time_frame>From birth to 36 Weeks PMA</time_frame>
    <description>Time (days) on mechanical ventilation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>Phase 1b open-label AT-100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily AT-100 via intratracheal administration for up to 2 doses (initial Phase 1b dose-escalation portion) or 7 doses (latter Phase 1b highest tolerated &amp; safety dose level tested portion).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b open-label air-sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Once daily air-sham via intratracheal administration for up to 2 doses (initial Phase 1b dose-escalation portion) or 7 doses (latter Phase 1b highest tolerated &amp; safety dose level tested portion).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AT-100</intervention_name>
    <description>reconstituted AT-100 for intratracheal administration</description>
    <arm_group_label>Phase 1b open-label AT-100</arm_group_label>
    <other_name>(rhSP-D)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Air-sham</intervention_name>
    <description>room air for intratracheal administration</description>
    <arm_group_label>Phase 1b open-label air-sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Preterm neonates born between 23 0/7 weeks to 28 6/7 weeks.&#xD;
&#xD;
          2. Intubated and on mechanical ventilation.&#xD;
&#xD;
          3. Receiving at least 1 dose of standard-of-care-indicated surfactant treatment&#xD;
             (Curosurf®) within 24 hours of birth.&#xD;
&#xD;
          4. Parent or legal guardian is able to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Weight at time of birth &lt; 400 g or &gt; 1,800 g.&#xD;
&#xD;
          2. Major apparent congenital abnormalities impacting cardio and pulmonary function.&#xD;
&#xD;
          3. Active DNR (Do Not Resuscitate) order in place.&#xD;
&#xD;
          4. Known pulmonary air leaks (e.g. pneumothorax and pneumomediastinum).&#xD;
&#xD;
          5. History of allergy or sensitivity to any surfactant or any component of the&#xD;
             Investigational Product (AT-100).&#xD;
&#xD;
          6. Birth mother has or had:&#xD;
&#xD;
               1. Known positive Hepatitis A, B, C, D or E diagnosis.&#xD;
&#xD;
               2. Known illness or exposure that, in the judgement of the Investigator, is serious&#xD;
                  enough to induce an immune deficiency such as Human Immunodeficiency Virus (HIV)&#xD;
                  and/or is receiving chemotherapy.&#xD;
&#xD;
               3. Known Sexually Transmitted Infection (STI).&#xD;
&#xD;
               4. Known Cytomegalovirus (CMV) active infection.&#xD;
&#xD;
               5. History or evidence of alcohol or drug abuse.&#xD;
&#xD;
          7. Concurrent enrollment in an investigational drug, device, or treatment modulation&#xD;
             trial.&#xD;
&#xD;
          8. Any condition or situation which, in the Investigator's judgement, puts the mother or&#xD;
             the neonate at significant risk, could confound the trial results, or may interfere&#xD;
             significantly with the mother's or neonate's participation in the trial.&#xD;
&#xD;
          9. Symptomatic and confirmed COVID-19 infection of the mother and/or neonate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul S. Kingma, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Airway Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc O. Salzberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Airway Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brenda L Poindexter, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neil P. Mills, BS</last_name>
    <phone>470-486-4688</phone>
    <email>mills@airwaytherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul S. Kingma, MD, PhD</last_name>
    <phone>513-770-9630</phone>
    <email>kingma@airwaytherapeutics.com</email>
  </overall_contact_backup>
  <link>
    <url>http://www.airwaytherapeutics.com</url>
    <description>Airway Therapeutics' corporate website</description>
  </link>
  <reference>
    <citation>Thébaud B, Goss KN, Laughon M, Whitsett JA, Abman SH, Steinhorn RH, Aschner JL, Davis PG, McGrath-Morrow SA, Soll RF, Jobe AH. Bronchopulmonary dysplasia. Nat Rev Dis Primers. 2019 Nov 14;5(1):78. doi: 10.1038/s41572-019-0127-7. Review.</citation>
    <PMID>31727986</PMID>
  </reference>
  <reference>
    <citation>Jensen EA, Dysart K, Gantz MG, McDonald S, Bamat NA, Keszler M, Kirpalani H, Laughon MM, Poindexter BB, Duncan AF, Yoder BA, Eichenwald EC, DeMauro SB. The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach. Am J Respir Crit Care Med. 2019 Sep 15;200(6):751-759. doi: 10.1164/rccm.201812-2348OC.</citation>
    <PMID>30995069</PMID>
  </reference>
  <reference>
    <citation>Sorensen GL. Surfactant Protein D in Respiratory and Non-Respiratory Diseases. Front Med (Lausanne). 2018 Feb 8;5:18. doi: 10.3389/fmed.2018.00018. eCollection 2018. Review.</citation>
    <PMID>29473039</PMID>
  </reference>
  <reference>
    <citation>Sato A, Whitsett JA, Scheule RK, Ikegami M. Surfactant protein-d inhibits lung inflammation caused by ventilation in premature newborn lambs. Am J Respir Crit Care Med. 2010 May 15;181(10):1098-105. doi: 10.1164/rccm.200912-1818OC. Epub 2010 Feb 4.</citation>
    <PMID>20133924</PMID>
  </reference>
  <reference>
    <citation>Ikegami M, Carter K, Bishop K, Yadav A, Masterjohn E, Brondyk W, Scheule RK, Whitsett JA. Intratracheal recombinant surfactant protein d prevents endotoxin shock in the newborn preterm lamb. Am J Respir Crit Care Med. 2006 Jun 15;173(12):1342-7. Epub 2006 Mar 23.</citation>
    <PMID>16556693</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchopulmonary Dysplasia</keyword>
  <keyword>Preterm</keyword>
  <keyword>Neonate</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Respiratory support</keyword>
  <keyword>recombinant human Surfactant Protein-D (rhSP-D)</keyword>
  <keyword>intratracheal</keyword>
  <keyword>air-sham</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

